Stephen K. Doberstein - Jun 3, 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc (DRNA)

Role: Director
Signature: /s/ Douglas W. Pagan, attorney-in-fact
Stock symbol: DRNA
Transactions as of: Jun 3, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/7/2021, 09:32 PM
Next filing: Dec 29, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Options Exercise		+3.33K			3.33K	Jun 3, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRNA	Restricted Stock Units	Options Exercise	$0	-3.33K	-100%	$0.00^*	0	Jun 3, 2021	Common Stock	3.33K		Direct	F1, F2
transaction	DRNA	Restricted Stock Units	Award	$0	+3.33K		$0.00	3.33K	Jun 3, 2021	Common Stock	3.33K		Direct	F1, F3
transaction	DRNA	Director Stock Option (Right to Buy)	Award	$0	+15K		$0.00	15K	Jun 3, 2021	Common Stock	15K	$30.47	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
F2	Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021.
F3	Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting.
F4	This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option will vest in full on the next regularly scheduled annual meeting of the stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.